tbuckley/cabot-search huggingface dataset:
Impact of tree-based interventions in addressing health and wellbeing outcomes in rural low-income and middle-income settings: a systematic review and meta-analysis
Authors: Peninah Murage, Blanca Anton, Faraja Chiwanga, Roberto Picetti, Tabby Njunge, Syreen Hassan, Sarah Whitmee, Jane Falconer, Hugh Sharma Waddington, Rosemary Green
Journal: The Lancet Planetary Health (2025)

The impact of nature-based solutions on human health is increasingly recognised; however, our understanding of the strength of evidence and the extent to which it supports policy and practice is insufficient. We aimed to assess the health and wellbeing impacts of solutions in low-income and middle-income settings in which trees are a central feature in the protection, restoration, and sustainable management of landscapes. For this systematic review and meta-analysis, we searched Web of Science, Embase, APA PsycInfo, MEDLINE ALL, Global Health, Global Index Medicus, GreenFILE, SciELO, EconLit, and Africa-Wide Information for studies that evaluated the impacts of relevant interventions on health and wellbeing. Searches were limited to records published from Jan 1, 2000, to the search date; an initial search was conducted on Nov 23, 2021, and was updated on Feb 27-28, 2023. We extracted data from studies comparing interventions with matched controls, calculated standardised mean differences, and pooled the effects using random-effects meta-analysis with adjustments for potential effect dependence. Studies were assessed for quality using seven risk-of-bias domains. Our search identified 23 402 studies, of which 54 were included in the meta-analysis. We found significant positive pooled effects for agricultural yields (standardised mean difference 0·41 [95% CI 0·11 to 0·70]), dietary diversity (0·10 [0·02 to 0·18]), total household income (0·21 [0·09 to 0·33]), poverty reduction (0·17 [0·07 to 0·27]), child growth (0·11 [0·00 to 0·22]), and self-reported wellbeing (0·21 [0·00 to 0·43]). Loss of income from timber production could be a negative outcome (-0·13 [-0·29 to 0·02]); however, these effects might be partially offset by increased income from non-timber forest products (0·32 [0·04 to 0·61]). Effects varied substantially by intervention type, with more positive effects associated with interventions in which the primary target was livelihood improvement than with interventions that targeted biodiversity or carbon mitigation. However, cautious interpretation is urged owing to the low certainty of the evidence. In conclusion, evidence suggests that tree-based solutions can support the health and wellbeing of the implementing communities. Such evidence strengthens the case for aligning health objectives with the goals of nature-based solutions by making community wellbeing an integral component of conservation programmes. Future studies should examine a wider range of outcomes that have direct relevance for health.
Mapping the landscape of biliary tract cancer in Europe: challenges and controversies
Authors: Lorenza Rimassa, Shahid Khan, Bas Groot Koerkamp, Stephanie Roessler, Jesper B Andersen, Chiara Raggi, Ana Lleo, Jean-Charles Nault, Julien Calderaro, Chiara Gabbi, Jakob N Kather, Jesus M Banales, Irene Bargellini, Helen Morement, Marcin Krawczyk, Paraskevi A Farazi, Guido Carpino, Matias A Avila, Anna Saborowski, Vincenzo Cardinale, Chiara Braconi, Rocio I R Macias
Journal: The Lancet Regional Health - Europe (2025)

Biliary tract cancer (BTC) is becoming more common worldwide, with geographic differences in incidence and risk factors. In Europe, BTC may be associated with primary sclerosing cholangitis, lithiasis, and liver cirrhosis, but is more frequently observed as a sporadic disease. BTC increasingly affects patients under 60 years, resulting in a significant social and economic burden. Early diagnosis remains challenging due to vague symptoms in 50% of patients with BTC, and lack of specific biomarkers, resulting in late presentation and poor prognosis. The identification of patients at increased risk and reliable biomarkers require collaborative efforts to make faster progress. This Series paper highlights the disparities in access to diagnostic tools and multidisciplinary care in Europe, particularly in economically disadvantaged regions, while identifying priority areas for improvement. Addressing these inequities requires harmonised guidelines, accelerated pathways to curative treatments, and improved awareness among healthcare professionals and the public. Multidisciplinary teams (MDTs) are crucial for the diagnosis of BTC and for improving patient outcomes, yet inconsistencies exist in their implementation not only between different countries, but also between different centres within a country. Collaboration and standardisation of diagnostic and treatment protocols across Europe are essential to effectively address the management of patients with BTC.
Noncoding RNA-encoded peptides in cancer: biological functions, posttranslational modifications and therapeutic potential
Authors: Shiming Tan, Wenjuan Yang, Zongyao Ren, Qiu Peng, Xuemeng Xu, Xianjie Jiang, Zhu Wu, Linda Oyang, Xia Luo, Jinguan Lin, Longzheng Xia, Mingjing Peng, Nayiyuan Wu, Yanyan Tang, Yaqian Han, Qianjin Liao, Yujuan Zhou
Journal: Journal of Hematology & Oncology (2025)

In the present era, noncoding RNAs (ncRNAs) have become a subject of considerable scientific interest, with peptides encoded by ncRNAs representing a particularly promising avenue of investigation. The identification of ncRNA-encoded peptides in human cancers is increasing. These peptides regulate cancer progression through multiple molecular mechanisms. Here, we delineate the patterns of diverse ncRNA-encoded peptides and provide a synopsis of the methodologies employed for the identification of ncRNAs that possess the capacity to encode these peptides. Furthermore, we discuss the impacts of ncRNA-encoded peptides on the biological behavior of cancer cells and the underlying molecular mechanisms. In conclusion, we describe the prospects of ncRNA-encoded peptides in cancer and the challenges that need to be overcome.
Direct oral anticoagulants versus vitamin K antagonists for cerebral venous thrombosis (DOAC-CVT): an international, prospective, observational cohort study
Authors: Anita van de Munckhof, Mayte Sánchez van Kammen, Turgut Tatlisumak, Katarzyna Krzywicka, Sanjith Aaron, Florina Antochi, Antonio Arauz, Miguel A Barboza, Adriana B Conforto, Daniel Galdames Contreras, Mirjam R Heldner, Maria Hernández-Pérez, Sini Hiltunen, Xunming Ji, Wayneho Kam, Timothy J Kleinig, Espen S Kristoffersen, Ronen R Leker, Robin Lemmens, Sven Poli, Mohammad Wasay, Teddy Wu, Nilüfer Yeşilot, Jian Chen, Maria Sofia Cotelli, Jelle Demeestere, Jiangang Duan, Nesrin Ergin, Tiago Esteves Freitas, Ana Gomes, Heleen M den Hertog, Erik Lindgren, Nicolas Martinez-Majander, Issa Metanis, Angel Miraclin, Lucia Jansi Rani, Y Muralidhar Reddy, Shafaq Saleem, Adrian Scutelnic, Sathish Shanmugasundaram, Ido R van den Wijngaard, Işıl Yazıcı Gençdal, Rik van Eekelen, Jelle Vellema, Marcel Arnold, Lia Neto, Saskia Middeldorp, Diana Aguiar de Sousa, Katarina Jood, Jukka Putaala, José M Ferro, Jonathan M Coutinho
Journal: The Lancet Neurology (2025)
Environmental and patient safety outcomes of a health-system Green Anesthesia Initiative (GAIA): a retrospective observational cohort study
Authors: Douglas A Colquhoun, David Hovord, Robyn Rachel, Yuan Yuan, Graciela B Mentz, Prabhat Koppera, Timur Z Dubovoy, Paul Picton, George A Mashour
Journal: The Lancet Planetary Health (2025)

Inhaled anaesthetics are greenhouse gases. However, changes in the delivery of inhaled anaesthetics can mitigate environmental impact. We hypothesised that system-wide changes to the delivery of anaesthesia care would reduce environmental harm without compromising patient outcomes. We launched the Green Anesthesia Initiative (GAIA) in March, 2022, with the aims of reducing the use of nitrous oxide, using less environmentally harmful inhaled fluorinated ethers, and increasing intravenous anaesthetic use. In this retrospective cohort study, we used electronic health record data from general anaesthetics performed on all patients older than 1 year between March 1, 2021, and Feb 28, 2023, at a single US academic medical centre across multiple sites, collecting data from before and after the introduction of GAIA. Patients with missing or invalid data recorded by the anaesthesia machine, patients given general anaesthetics for electroconvulsive therapy, and patients who met American Society of Anesthesiologists Physical Status Classification 6 were excluded. Using multivariable modelling, we compared estimated CO2, equivalents and, secondarily, anaesthetic dose, postoperative nausea and vomiting, pain scores on a 0-10 scale, and reports of intraoperative awareness with explicit recall. We recorded 45 692 patients pre-intervention (23 193 [50·8%] female, 22 494 [49·2%] male, five [<0·1%] unknown) and 47 199 post-intervention (23 981 [50·8%] female, 23 209 [49·2%] male, nine [<0·1%] unknown). After the implementation of GAIA, CO2, equivalents were reduced by 14·38 kg per patient (95% CI -14·68 to -14·07; p<0·0001). There was no clinically meaningful difference in median anaesthetic delivered (minimum alveolar concentration -0·02 [95% CI -0·02 to -0·01]; p<0·0001) nor pain scores (-0·34 [-0·39 to -0·29]; p<0·0001). Postoperative nausea and vomiting was unchanged (odds ratio 0·98 [95% CI 0·94-1·02]; p=0·26). A small number of definite intraoperative awareness events were reported in both periods (one pre-intervention and two post-intervention). A health-system wide intervention reduces greenhouse gas emissions attributable to anaesthesia care without detriment to patient outcomes. University of Michigan Medical School and National Institutes of Health.
Mycoplasma pneumoniae infection in adult inpatients during the 2023–24 outbreak in France (MYCADO): a national, retrospective, observational study
Authors: Ariane Gavaud, Matthieu Holub, Antoine Asquier-Khati, Karine Faure, Sophie Leautez-Nainville, Gwenael Le Moal, François Goehringer, David Luque Paz, Bérangère Arnould, Victor Gerber, Guillaume Martin-Blondel, Charles Declerck, Sandrine Gazaignes, Sophie Blanchi, Paul Loubet, Natacha Mrozek, Thomas Perpoint, Melanie Cresta, Morgane Mailhe, Alexandre Bleibtreu, Charles Cazanave, Cécile Bébéar, Valérie Pourcher, Florence Tubach, Romain Palich
Journal: The Lancet Infectious Diseases (2025)
The impacts of air pollution on mortality and hospital readmission among Medicare beneficiaries with Alzheimer's disease and Alzheimer's disease-related dementias: a national retrospective cohort study in the USA
Authors: Shuxin Dong, Danielle Braun, Xiao Wu, Maayan Yitshak-Sade, Deborah Blacker, Marianthi-Anna Kioumourtzoglou, Joel Schwartz, Daniel Mork, Francesca Dominici, Antonella Zanobetti
Journal: The Lancet Planetary Health (2025)

Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD) are prevalent neurodegenerative disorders, posing a critical worldwide public health challenge. Ambient air pollution has been identified as a potential risk factor for AD progression based on toxicological and epidemiological studies. We aimed to evaluate the impacts of air pollution-including fine particulate matter (PM2·5), nitrogen dioxide (NO2), summer ozone (O3), and oxidant-on readmission or death among Medicare enrollees previously hospitalised with an AD/ADRD diagnosis code. We constructed a population-based nationwide retrospective cohort including all Medicare fee-for-service beneficiaries (aged ≥65 years) in the contiguous USA (2000-16) hospitalised with AD/ADRD, and followed them up from the year after their first hospitalisation until (1) year of death (mortality cohort) and (2) year of second hospitalisation for any cause (readmission cohort). We calculated annual average PM2·5, NO2, summer O3, and oxidant concentrations for each individual at their residential ZIP code in each year after their first hospitalisation with AD/ADRD. We applied Cox proportional hazard models for the mortality and readmission cohorts stratifying on individual risk factors and adjusting for socioeconomic status, seasonal temperatures, and relative humidity. Our cohort consisted of 5 544 118 individuals, of whom 4 543 759 (82·0%) died and 3 880 894 (70·0%) were readmitted to the hospital during the study period. The average follow-up times were 3·34 years (SD 2·60) for the mortality cohort and 1·98 years (SD 1·65) for the readmission cohort. In both the mortality and readmission cohorts we found significant associations with each pollutant. For an IQR increase in NO2, we found a hazard ratio (HR) for mortality of 1·012 (95% CI 1·009-1·015) and an HR for readmission of 1·110 (1·104-1·117). In the readmission cohort, we found an HR of 1·084 (1·079-1·089) for an IQR increase (3·87 μg/m3) in PM2·5. The results slightly decreased in multi-pollutant models. The results of effect modification for mortality and readmission varied by pollutant, but higher risks were found among Black males and among those eligible for Medicaid in general. We provide new evidence that among a susceptible population with previous AD/ADRD-related hospitalisations, annual air pollution exposure since first hospitalisation is associated with risk of readmission and death. National Institute on Aging.
Impact of a 10-year shift in ambient air quality on mortality in Canada: a causal analysis of multiple pollutants
Authors: Hong Chen, Matthew Quick, Jay S Kaufman, Chen Chen, Jeffrey C Kwong, Aaron van Donkelaar, Randall V Martin, Michael Tjepkema, Tarik Benmarhnia, Richard T Burnett
Journal: The Lancet Planetary Health (2025)

The impact of past air quality improvements on health and equity at low pollution levels near the revised WHO air quality guidelines remains largely unknown. Less is known about the influence of simultaneous reductions in multiple major pollutants. Leveraging real-world improvements in air quality across Canada, we sought to directly evaluate their health benefits by quantifying the impact of a joint shift in three criteria pollutants on mortality in a national cohort. In this population-based cohort study, we assembled a cohort of 2·7 million adults living in Canada in 2007 who were followed up through 2016. Annual mean concentrations of fine particulate matter (PM2·5), nitrogen dioxide (NO2), and ozone (O3) were assigned to participants' residential locations. For each pollutant individually and combined, we conducted a causal analysis of the impact of the decadal shift in annual exposure from the pre-baseline level (2004-06) on the risk of non-accidental mortality using the parametric g-formula, a structural causal model. To check the robustness of our results, we conducted multiple sensitivity analyses, including exploring alternative exposure scenarios. We also evaluated differential benefits across regions and socio-demographic subgroups. Between 2007 and 2016, annual mean exposures to PM2·5 and NO2 decreased (from 7·1 μg/m3 [SD 2·3] to 5·5 μg/m3 [1·9] for PM2·5 and from 11·1 ppb [SD 6·6] to 8·0 ppb [4·9] for NO2), whereas O3 declined initially and then rebounded (from 38·6 [SD 8·3] ppb to 36·0 [6·0] ppb and then 38·1 [5·4] ppb). Compared to pre-baseline (2004-06) levels, the joint change in the pollution exposures beginning in 2007 resulted in, per million population, 70 (95% CI 29-111) fewer deaths by 2009, 416 (283-549) fewer deaths by 2012, and 609 (276-941) fewer deaths by 2016, corresponding to a -0·7% change in mortality risk over the decade. Stratified analyses showed greater beneficial impacts in men, adults aged 50 years and older, low income-earners, and residents in regions undergoing substantial air quality improvements. Had all regions experienced pollution reductions similar to the most improved region, approximately three times as many deaths would have been averted (2191 fewer deaths per million). Conversely, if the observed air quality improvements had been delayed in all regions by 3 years, there would have been 429 more deaths per million by 2016. In Canada, substantial health gains were associated with air quality improvements at levels near the revised WHO guidelines between 2007 and 2016, with notable heterogeneity observed across socio-demographic subgroups and regions. These findings indicate that modest declines in air pollution can considerably improve health and equity, even in low-exposure environments. Health Canada.
The environment in global health governance: an analysis of environment-related resolutions adopted at the World Health Assembly from 1948 to 2023
Authors: Mylan Evrard, Alicia Rieckhoff, Leah Shipton, Peter Søgaard Jørgensen, Jean-Luc Falcone, Roland Bouffanais, Bastien Chopard, Nicolas Levrat, Didier Wernli
Journal: The Lancet Planetary Health (2025)

The concept of planetary health underscores the intricate relationship between environmental concerns and global health. This interconnection raises an important question related to cross-sectoral policy development: to what extent are environmental issues integrated into global health governance? To address this question, this study examines resolutions adopted by the World Health Assembly (WHA) from 1948 to 2023. Based on a systematic text search for environmental issues, this study examines the evolution of the occurrence and content of resolutions adopted by the WHA and the structure and pattern of connectivity of the normative network of resolutions regarding environment-related resolutions from 1948 to 2023. Environment-related resolutions were processed in the Python environment using relevant packages, such as Pandas, Numpy, and Matplotlib. Regular expressions were employed to identify citations among resolutions and construct a directed citation network. The network was then examined using NetworkX and Graph-Tool. Despite important variations in the attention dedicated to environmental issues in resolutions adopted by the WHA, the proportion of environment-related resolutions adopted each year has increased. The number of topics and their diversity have also expanded. Although environment-specific resolutions are well connected to each other, they are more weakly connected to environment-related resolutions, and not well connected to non-environment-related resolutions, suggesting potential silos in policy development. This study shows that several topical entry points exist for a deeper integration of environmental concerns in global health governance. The findings of this study indicate not only the growing reference to environmental concerns in global health governance, but also an evolution of the understanding of the environment as a key driver of the health of the people. However, there remains room for more comprehensive integration across all areas of global health policy. The study emphasises both the need for active participation in global environmental governance processes that affect health and the importance of minimising the health sector's contribution to environmental problems. None.
Amyotrophic lateral sclerosis caused by hexanucleotide repeat expansions in C9orf72: from genetics to therapeutics
Authors: Sarah Mizielinska, Guillaume M Hautbergue, Tania F Gendron, Marka van Blitterswijk, Orla Hardiman, John Ravits, Adrian M Isaacs, Rosa Rademakers
Journal: The Lancet Neurology (2025)
Climate change effects on the human gut microbiome: complex mechanisms and global inequities
Authors: Elena Litchman
Journal: The Lancet Planetary Health (2025)

Ongoing global climate change is affecting all aspects of life on Earth, including human health. The gut microbiota is an important determinant of health in humans and other organisms, but how climate change affects gut microbiota remains largely unexplored. In this Review, I discuss how the changing climate might affect gut microbiota by altering the quantity and quality of food, as well as environmental microbiomes, such as enteric pathogen pressure and host physiology. Climate change-induced variability in food supply, shifts in elemental and macromolecular composition of plant and animal food, the proliferation of enteric pathogens, and the direct effects of high temperatures on gut physiology might alter gut microbiota in undesirable ways, increasing the health burden of climate change. The importance of different pathways might depend on many geographical, economic, and ecological factors. Microbiomes of populations in low-income countries might be disproportionally affected through greater climate change effects and poor mitigation on diet, pathogen burden, and host physiology.
Clinical insights in enzyme replacement therapy for metabolic storage disorders: lessons from Pompe disease
Authors: Nadine A M E van der Beek, Maudy T M Theunissen, Johanna M P van den Hout, Wilhelmus W M Pijnappel, Benedikt Schoser, Pascal Laforêt, Giancarlo Parenti, Pieter A van Doorn, Ans T van der Ploeg
Journal: The Lancet Neurology (2025)
New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across Europe
Authors: Lorenza Rimassa, Angela Lamarca, Grainne M O'Kane, Julien Edeline, Mairéad G McNamara, Arndt Vogel, Matteo Fassan, Alejandro Forner, Timothy Kendall, Jorge Adeva, Andrea Casadei-Gardini, Lorenzo Fornaro, Antoine Hollebecque, Maeve A Lowery, Teresa Macarulla, David Malka, Elene Mariamidze, Monica Niger, Anu Ustav, John Bridgewater, Rocio I R Macias, Chiara Braconi
Journal: The Lancet Regional Health - Europe (2025)

In recent years, treatment options for patients with advanced biliary tract cancer (BTC) have increased significantly due to the positive results from phase 2/3 clinical trials of immune checkpoint inhibitors, combined with chemotherapy, and molecularly targeted agents. These advances have led to the need for molecular testing to identify actionable alterations and patients amenable to targeted therapies. However, these improvements have brought with them many questions and challenges, including the identification of resistance mechanisms and therapeutic sequences. In this Series paper we aim to provide an overview of the current systemic treatment options for patients with BTC, highlighting disparities in access to innovative treatments and molecular testing across European countries, which lead to inequalities in the possibilities of treating patients with advanced BTC. We also discuss how ongoing European collaborative projects, such as the COST Action Precision-BTC-Network CA22125, supported by COST (European Cooperation in Science and Technology), linked to the European Network for the Study of Cholangiocarcinoma (ENSCCA), can help overcome these disparities and improve the current scenario.
Effect of pre-transplant cytoreductive therapy on the outcomes of patients with MDS or secondary AML evolving from MDS undergoing allo-HSCT: a secondary analysis of an RCT
Authors: Rongtao Xue, Min Dai, Erlie Jiang, Xueying Ou, Fen Huang, Zhiping Fan, Na Xu, Chenhua Yan, Danian Nie, Xinquan Liang, Hong Chen, Jieyu Ye, Ling Jiang, Hui Liu, Hua Jin, Ren Lin, Yu Zhang, Jing Sun, Mingzhe Han, Qifa Liu, Yu Wang, Li Xuan
Journal: Blood Cancer Journal (2025)